articleTop 1% cited
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Journal of Pharmacology and Experimental Therapeutics · 2012 · Vol. 343(2) · pp. 342–350
Flavio Solca✉(Boehringer Ingelheim (Germany))G. Dahl(Boehringer Ingelheim (Austria))Andreas Zoephel(Boehringer Ingelheim (Austria))Gerd Bader(Boehringer Ingelheim (Austria))Michael P. Sanderson(Boehringer Ingelheim (Austria))Christian Klein(Boehringer Ingelheim (Germany))Oliver Kraemer(Boehringer Ingelheim (Germany))Frank Himmelsbach(Boehringer Ingelheim (Germany))Eric Haaksma(Boehringer Ingelheim (Austria))Guenther R. Adolf(Boehringer Ingelheim (Germany))
HER2/EGFR in Cancer ResearchQuinazolinone synthesis and applicationsChronic Lymphocytic Leukemia ResearchAfatinibEpidermal growth factor receptorErbBT790MReceptorChemistryEGFR inhibitorsAcrylamideCancer researchBiology
MeSH terms
AfatinibProto-Oncogene MasAnimalsCells, CulturedCrystallographyData Interpretation, StatisticalHumansModels, MolecularMolecular Sequence DataPhosphorylationPhosphotransferasesProtein ConformationQuinazolinesSpectrum AnalysisStructure-Activity Relationship
Citations
858
FWCI
28.73
field-weighted impact
References
39
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
FDA-approved small-molecule kinase inhibitors
Trends in Pharmacological Sciences · 2015 · 991 citations
References
Untangling the ErbB signalling network
Nature Reviews Molecular Cell Biology · 2001 · 6,890 citations
The resurgence of covalent drugs
Nature Reviews Drug Discovery · 2011 · 1,809 citations
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
The EMBO Journal · 1997 · 1,569 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene · 2008 · 1,434 citations
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet · 2010 · 7,196 citations
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Cancer Research · 2004 · 1,108 citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.